Personalized Medicine

Balancing Innovation and Value in Cancer Care: Spotlight on Non–Small-Cell Lung Cancer Treatment

February 2017, Vol 8, No 1, Supplement 1: Balancing Innovation and Value in Cancer Care: Spotlight on Non–Small-Cell Lung Cancer Treatment - Lung Cancer

The rising cost of healthcare, including cancer care, is an established trend in the United States. In 2015, Americans spent $3.2 trillion (nearly $10,000 per person) on healthcare, including hospital inpatient and outpatient care, physicians’ services, and prescription drugs. The National Cancer Institute estimates that by 2020, the annual cost of healthcare for Americans with cancer will reach $156 billion; based on current trends, this means that cancer care will represent approximately 20% of the country’s annual healthcare expenditures. [ Read More ]

American Society of Hematology 2016: Leukemia Highlights

February 2017, Vol 8, No 1 - Leukemia

  • 5-Year Ibrutinib Therapy in Treatment-Naïve Patients with Relapsed or Refractory CLL or SLL
  • Updated Safety and Efficacy Data for Ibrutinib as First-Line Treatment in Older Patients with CLL or SLL
  • Long-Term Follow-Up of Chlorambucil plus Rituximab Combination as Frontline Therapy for Elderly and/or Unfit Patients with CLL, Including Risk Stratification
  • Reviewing the Demographics and First-Line Treatment Patterns in Patients with CLL
  • Comparing Healthcare Utilization of 2 Drug Regimens in Patients with CLL
[ Read More ]

American Society of Hematology 2016: Multiple Myeloma Highlights

February 2017, Vol 8, No 1 - Multiple Myeloma

  • Adding Daratumumab to Lenalidomide and Dexamethasone in Previously Treated Patients with Relapsed or Refractory Multiple Myeloma Improves Outcomes
  • Real-World Evidence Regarding Newer Treatment Options, Overall Survival, and Healthcare Costs in Patients with Multiple Myeloma
  • Long-Term Analysis of the CASTOR Trial: Adding Daratumumab to Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
  • The Use of Early Response Can Guide Treatment Selection in Patients with Newly Diagnosed Multiple Myeloma
  • Using Montelukast to Reduce Infusion Reactions in Patients with Relapsed or Refractory Multiple Myeloma
[ Read More ]

Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Patients with Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

February 2017, Vol 8, No 1 - Multiple Myeloma

San Diego, CA—The addition of venetoclax (Venclexta) to bortezomib (Velcade) and dexamethasone yields high response rates in patients with relapsed or refractory multiple myeloma, especially in patients with disease that is not refractory to bortezomib and who received 1 to 3 previous lines of therapy, according to findings presented by Philippe Moreau, MD, Department of Hematology, Nantes University Hospital, France, at the 2016 American Society of Hematology meeting. [ Read More ]

Novel Hypomethylating Agent Active in Patients with High-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Charles Bankhead

February 2017, Vol 8, No 1 - Emerging Therapies

San Diego, CA—Approximately 33% of patients with newly diagnosed, higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) attained complete responses with the novel hypomethylating agent guadecitabine, according to results of a phase 2 study reported by Guillermo Montalban-Bravo, MD, M.D. Anderson Cancer Center, Houston, at the 2016 American Society of Hematology meeting. [ Read More ]

Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in AML or High-Risk MDS

Wayne Kuznar

February 2017, Vol 8, No 1 - Emerging Therapies

San Diego, CA—Adding the investigational smoothened (SMO) receptor inhibitor glasdegib to low-dose cytarabine (Depo­Cyt) significantly increased overall survival (OS) compared with low-dose cytarabine monotherapy in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who were ineligible for intensive chemotherapy, according to a phase 2 study presented by Jorge E. Cortes, MD, Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, at the 2016 American Society of Hematology meeting. [ Read More ]

The Hematology Pipeline Features New Immune Therapies, and Targeted Agents

Wayne Kuznar

February 2017, Vol 8, No 1 - Emerging Therapies

San Diego, CA—Immunotherapy, especially chimeric antigen receptor (CAR) T-cell therapy, and targeted agents continue to dominate the pipeline of therapies for hematologic malignancies. The following agents are some of the main drugs showing promising results that are under investigation and were featured at the 2016 American Society of Hematology meeting. [ Read More ]

CAR T-Cell Therapy Succeeds in Aggressive Lymphoma

Phoebe Starr

February 2017, Vol 8, No 1 - Emerging Therapies

San Diego, CA—The investigational chimeric antigen receptor (CAR) T-cell therapy KTE-C19 achieved complete responses that were durable for >1 year in more than 75% of patients with aggressive lymphomas who had no other effective treatment options, according to results from the phase 2 pivotal clinical trial ZUMA-1 that were presented by Sattva S. Neelapu, MD, Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center, at the 2016 American Society of Hematology meeting. [ Read More ]